Skeletal muscle is one of the most abundant tissue types in the human body, but has proven difficult to produce in large quantities in the lab. Unlike other cell types, such as heart cells, neurons and cells found in the gut, previous attempts to efficiently and accurately derive muscle cells from pre-cursor cells or culture have not been fruitful. In a new study published this week in Nature Biotechnology, investigators from Brigham and Women's Hospital (BWH) report that by identifying and mimicking important developmental cues, they have been able to drive cells to grow into muscle fibers, producing millimeter-long muscle fibers capable of contracting in a dish and multiplying in large numbers. This new method of producing muscle cells could offer a better model for studying muscle diseases, such as muscular dystrophy, and for testing out potential treatment options.
Previous studies have used genetic modification to create small numbers of muscle cells in the lab, but the research team, led by investigators from BWH and the Harvard Stem Cell Institute, wanted a technique that would allow them to grow large numbers of muscle cells efficiently for use in clinical applications.
"We took the hard route: we wanted to recapitulate all of the early stages of muscle cell development that happen in the body and recreate that in a dish in the lab," said corresponding author Olivier Pourquie, PhD, of BWH's Department of Pathology and the Department of Genetics at Harvard Medical School. "We analyzed each stage of early development, and generated cell lines that glowed green when they reached each stage. Going step by step, we managed to mimic each stage of development and coax cells toward muscle cell fate."
The team found that a combination of secreted factors that are important at early embryonic stages are also essential for stimulating differentiation - or the specialization of stem cells into particular cell types - in the lab. Using just the right recipe for differentiation, the team was able to produce long, mature fibers in a dish, derived from mouse or human pluripotent stem cells. They also cultured stem cells from the mouse model of Duchenne muscular dystrophy, observing the striking branched pattern that dystrophin-deficient muscle fibers show in the body.
The research team was also able to produce more immature cells known as satellite cells which, when grafted into a mouse model of Duchenne muscular dystrophy, produced muscle fibers. Further studies will be needed to determine if the new strategy could be optimized to develop cell therapies for treating degenerative diseases in humans.
In addition to developing a better model for Duchenne muscular dystrophy, the new protocol may also be useful for studying other muscle diseases such as sarcopenia (degenerative muscle loss), cachexia (wasting away of muscle associated with severe illness) and other muscular dystrophies.
"This has been the missing piece: the ability to produce muscle cells in the lab could give us the ability to test out new treatments and tackle a spectrum of muscle diseases," said Pourquie.
This work was supported by the European Research Council, the Stowers Institute for Medical Research, the Howard Hughes Medical Institute, the FP7 EU grant Plurimes (agreement no. 602423) and by a strategic grant from the French Muscular Dystrophy Association (AFM).
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 4.2 million annual patient visits, nearly 46,000 inpatient stays and employs nearly 16,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $600 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH continually pushes the boundaries of medicine, including building on its legacy in transplantation by performing a partial face transplant in 2009 and the nation's first full face transplant in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials groups. For more information, resources and to follow us on social media, please visit BWH's online newsroom.